About 200 reports

Its products target the gastrointestinal, metabolic, genitourinary, musculoskeletal, inflammation, ophthalmic, neurology, and pulmonary therapeutic areas.

  • Diabetes
  • Hormone
  • Hospital
  • Therapy
  • Novo Nordisk Group

Headquartered in London, UK, the company engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammatory diseases worldwide.

  • Hormone
  • Allergan plc
  • Bayer AG
  • Merck & Co., Inc.
  • Pfizer Inc.

pleurisy, pleural effusion, pneumonitis, pulmonary hypertension, and interstitial lung disease) Gastrointestinal (e. g., nausea, dyspepsia, and abdominal pain) Neuropsychiatric (e. g., seizure and psychosis) Hematologic (e. g., cytopenias such as leukopenia, lymphopenia, anemia, or thromboc

  • Hormone
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • MedImmune, LLC
  • Pfizer Inc.

It is active in therapeutic areas of Central Nervous System (CNS), Cardiovascular (CV), gastrointestinal, diabetology, anti-infective and pain management segments.

  • Hormone
  • Biocon Limited
  • Hospira, Inc.
  • Mylan Inc.
  • Sandoz Inc.

Systemic tetracycline may cause gastrointestinal upset, nausea, diarrhea, and vaginal yeast infection.

  • Antifungal
  • Autoimmune Disease
  • Dermatological Condition
  • Hormone
  • Pharmaceutical

These areas include some of the world' s most serious illnesses and together represent a major worldwide burden of disease: cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory & inflammation.

  • Hormone
  • China
  • AstraZeneca Pharmaceutical Co., Ltd
  • Bristol-Myers Squibb Company
  • Zhejiang Xianju Pharmaceutical Co., Ltd
  • and Forecasts (Billion Yuan)

ALTERNATIVELY, ANTAGONISM OF ##-HT## - A RECEPTOR THAT IS INVOLVED IN THE REGULATION OF NAUSEA, VOMITING, AND THE GASTROINTESTINAL TRACT - COULD COUNTERACT THE Serotonin Modulators and Stimulators Chapter IV DEPRESSION TREATMENT DRUGS SALES VOLUMES AND FORECASTS UNDESIRABLE INCREASE IN ACTIVA

  • Antidepressant
  • Hormone
  • Therapy
  • China
  • Demand
  • Benazepril is prescribed off-label in both dogs and cats to treat CHF.

NSAIDS are associated with gastrointestinal ulcers/ perforations, and kidney and liver toxicity.

  • Hormone
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Merial Limited
  • Zoetis Inc.

These areas include some of the world' s most serious illnesses and together represent a major worldwide burden of disease: cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory & inflammation.

  • Hormone
  • China
  • AstraZeneca Pharmaceutical Co., Ltd
  • Bristol-Myers Squibb Company
  • Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

This enables the drug to bypass the gastrointestinal tract.

  • Hormone
  • AbbVie Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Pfizer Inc.

The company produces and markets high-quality products and biologics in the areas of gastrointestinal disease, neurology, psychiatry, immunology, pain control, infectious disease, and oncology.

  • Hormone
  • China
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd
  • Beijing Novartis Pharma Ltd

The company produces and markets high-quality products and biologics in the areas of gastrointestinal disease, neurology, psychiatry, immunology, pain control, infectious disease, and oncology.

  • Hormone
  • China
  • Bayer Schering Pharmaceutical Co., Ltd
  • Roche Group
  • Shenzhen Main Luck Pharmaceuticals Inc.
  • Latest Clinical Trials News on Irritable Bowel Syndrome

Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, E## Countries (%), 2015* Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, E## Countries (%), 2015* Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trial

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Hormone
  • Pharmaceutical
  • J&J'S PROSTATE CANCER PORTFOLIO ASSESSMENT, 2014

gastrointestinal stromal tumors).

  • Hormone
  • Prostate Cancer
  • Astellas Pharma Inc.
  • Bayer AG
  • PROVENGE group

Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, E## Countries (%), 2015* Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, E## Countries (%), 2015* Proportion of Non Alcoholic Fatty Liver Disease

  • Hormone
  • World
  • AstraZeneca PLC
  • Galmed International Ltd.
  • Intercept Pharmaceuticals, Inc.
  • 7.10.7. KEY CLINICAL TRIAL RESULTS
  • MYCAPSSA™ / OCTREOLIN™ / ORAL OCTREOTIDE: CURRENT STATUS OF DEVELOPMENT

THIS IS DONE TO DECREASE THE PROBABILITY OF GASTROINTESTINAL SYMPTOMS.

  • Endocrine Disease
  • Hormone
  • United States
  • LipimetiX Development LLC
  • Novartis AG
  • NEW DEVELOPMENTS IN HORMONE DRUG DELIVERY

By avoiding the gastrointestinal system, the drug is less likely to cause nausea.

  • Hormone
  • Generex Biotechnology Corporation
  • Nitto Denko Corporation
  • Noven Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.

Cardiovascular Drugs Respiratory Drugs Anti-cancer Drugs CNS Drugs The Others segment includes dermatology, genitourinary, gastrointestinal, and endocrine drugs.

  • Anti-Infective
  • Hormone
  • Japan
  • Meiji Seika Pharma Co., Ltd.
  • Nipro Corporation
  • Patient Details

Non serious Body system/ preferred term Not serious adverse event (all excluding tolerability) Gastrointestinal disordersall Abdominal discomfort Abdominal distension Abdominal pain Abdominal pain, lower Abdominal pain, upper Abdominal tenderness Constipation Diarrhoea Dry mouth Flatule

  • Hormone
  • World
  • Ferring International Center S.A.
  • IBSA Institut Biochimique S.A.
  • Merck & Co., Inc.

References P##(SHC) Therapeutic Area/ Disease Indications Diabetes Gastrointestinal lesions University of Bari Aldo Moro, Italy.

  • Hormone
  • United States
  • MC2 Biotek Group
  • POXEL SA
  • XOMA Corporation

IT ALSO COMES WITH A WARNING REGARDING GASTROINTESTINAL (GI) SYMPTOMS, INCLUDING NAUSEA, VOMITING, AND DIARRHEA, AS WELL AS RENAL FAILURE, AND IS NOT RECOMMENDED FOR USE IN PATIENTS WITH IMPAIRED HEPATIC FUNCTION (JEVTANA PACKAGE INSERT, 2014).

  • Hormone
  • World
  • Astellas Pharma Inc.
  • OncoGenex Pharmaceuticals, Inc.
  • PROVENGE group

IT ALSO COMES WITH A WARNING REGARDING GASTROINTESTINAL (GI) SYMPTOMS, INCLUDING NAUSEA, VOMITING, AND DIARRHEA, AS WELL AS RENAL FAILURE, AND IS NOT RECOMMENDED FOR USE IN PATIENTS WITH IMPAIRED HEPATIC FUNCTION (JEVTANA PACKAGE INSERT, 2014).

  • Hormone
  • World
  • Astellas Pharma Inc.
  • OncoGenex Pharmaceuticals, Inc.
  • PROVENGE group
  • Clinical Trial profile. 17 Trial Title
  • Clinical Trial profile. 12 Trial Title

Proportion of Hepatorenal Syndrome to Gastrointestinal Clinical Trials, E## Countries (%), 2016* Proportion of Hepatorenal Syndrome to Gastrointestinal Clinical Trials, E## Countries (%), 2016* Proportion of Hepatorenal Syndrome to Gastrointestinal Clinical Trials, E## Countr

  • Digestive System Disorder
  • Hormone
  • World
  • Product Initiative
  • Mallinckrodt plc

gastrointestinal geographic atrophy fundus autofluorescence fluorescein angiogram eicosapentaenoic acid diabetic macular edema docosahexaenoic acid cardiovascular disease central retinal thickness CFT: CME: CMT: CNV: CRT: CRVO: CSME: CVD: dAMD: DHA: DME: DOG: DRCR: EPA: EphMRA: ETDRS: EuRet

  • Eye Disease
  • Hormone
  • Therapy
  • Alimera Sciences, Inc.
  • Allergan plc
  • has been approved unanimously by the Boards of Directors of both Shire and NPS Pharma.
  • GLEPAGLUTIDE - DRUG PROFILE

NPS is also advancing preclinical studies to evaluate teduglutide as a possible treatment for gastrointestinal mucositis, a complication of certain cancer treatments, and gastrointestinal disorders that affect premature infants.

  • Hormone
  • Europe
  • United States
  • World
  • Product Initiative
  • Clinical Trial profile. 179 Trial Title
  • Target

CIRRHOSIS THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY TRIAL STATUS, 2017* CLINICAL TRIALS BY E## COUNTRIES: PROPORTION OF CIRRHOSIS TO GASTROINTESTINAL CLINICAL TRIALS Among the E## (Brazil, Russia, India, China, Mexico, Turkey and Indonesia) countries, China have the highest proportion of

  • Clinical Trial
  • Cytokine
  • Digestive System Disorder
  • Hormone
  • World
  • Target
  • Clinical Trial profile. 451 Trial Title
  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Hormone
  • Therapy
  • Target
  • Clinical Trial profile. 49 Trial Title

PROPORTION OF EOSINOPHILIC ESOPHAGITIS TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* PROPORTION OF EOSINOPHILIC ESOPHAGITIS TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* PROPORTION OF EOSINOPHILIC ESOPHAGITIS TO GASTROINTESTINAL CLINICAL TRIAL

  • Digestive System Disorder
  • Healthcare
  • Hormone
  • World
  • Product Initiative
  • Target
  • Clinical Trial profile. 9 Trial Title
  • Clinical Trial
  • Diabetes
  • Hormone
  • World
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

PROPORTION OF DIABETIC GASTROPARESIS TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF DIABETIC GASTROPARESIS TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* As of July 2017, there were ## clinical trials in Phase II, of which two clinical tria

  • Chronic Disease
  • Hormone
  • World
  • Product Initiative
  • Allergan plc